众生药业(002317) - 2019 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2019 was CNY 614,266,791.99, representing a 2.82% increase compared to CNY 597,441,677.65 in the same period last year[9]. - Net profit attributable to shareholders for Q1 2019 was CNY 125,995,933.31, up 2.95% from CNY 122,381,342.76 year-on-year[9]. - The net cash flow from operating activities improved significantly to CNY 74,410,224.39, a 254.36% increase from a negative CNY 48,206,417.76 in the previous year[9]. - Basic and diluted earnings per share remained stable at CNY 0.15, unchanged from the same period last year[9]. - The weighted average return on net assets was 3.15%, slightly down from 3.25% in the previous year[9]. - The company reported a significant increase in financial expenses, which surged by 2490.16% to CNY 7,928,354.60, influenced by higher interest income and loan interest expenses[25]. - The company's net profit for the current period is not explicitly stated, but the increase in retained earnings to CNY 1,032,281,474.67 from CNY 951,017,052.38 suggests positive financial performance[63]. - The total comprehensive income for the current period is CNY 127,499,008.57, compared to CNY 121,735,046.69 in the previous period, reflecting a growth of 4.67%[71]. Assets and Liabilities - The total assets at the end of the reporting period reached CNY 5,809,673,117.68, marking a 10.78% increase from CNY 5,244,336,318.08 at the end of the previous year[9]. - The total liabilities increased, with long-term borrowings rising by 65.76% to CNY 576,000,000.00, reflecting new bank acquisition loans[25]. - Total current assets increased to CNY 2,969,637,634.33 from CNY 2,396,077,483.00, representing a growth of approximately 23.9%[47]. - Total liabilities rose to CNY 1,650,967,793.69, up from CNY 1,293,457,967.78, indicating an increase of about 27.7%[50]. - The company's total assets reached CNY 5,809,673,117.68, compared to CNY 5,244,336,318.08, marking a growth of approximately 10.8%[53]. - The total equity attributable to shareholders increased to CNY 4,065,786,268.10 from CNY 3,903,000,073.03, showing an increase of approximately 4.2%[53]. Cash Flow - As of March 31, 2019, cash and cash equivalents increased by 61.44% to CNY 1,475,496,612.66 compared to CNY 913,944,459.02 at the end of 2018[25]. - The net increase in cash and cash equivalents was CNY 546,633,288.87, a dramatic rise of 5817.25% compared to the previous period[28]. - Operating cash inflow for the current period reached ¥539,404,919.37, an increase of 8.3% compared to ¥498,623,745.65 in the previous period[82]. - Net cash flow from financing activities was ¥489,721,914.14, up from ¥227,156,266.63 in the previous period, indicating strong financing activity[85]. - The ending balance of cash and cash equivalents increased to ¥1,475,496,612.66, compared to ¥913,944,459.02 in the previous period, reflecting a net increase of ¥546,633,288.87[84]. Shareholder Information - The total number of shareholders at the end of the reporting period was 31,951[12]. - As of March 31, 2019, the company repurchased a total of 9,148,707 shares, accounting for 1.12% of the total share capital, with a total payment of approximately RMB 80.22 million[34]. - The highest transaction price during the share repurchase was RMB 10.25 per share, while the lowest was RMB 7.77 per share[34]. Investments and Financing - Guangdong Zhongsheng Pharmaceutical Co., Ltd. completed a capital increase of USD 15.8 million for its subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., changing its registered capital from RMB 100 million to RMB 119.75 million, with the company's ownership percentage decreasing from 92.50% to 77.24%[29]. - The company applied for a merger loan of up to RMB 250 million from China Construction Bank for acquiring Guangdong Yishu Pharmaceutical Co., Ltd., with a loan term of up to 7 years[29]. - The company reported cash inflow from borrowings amounting to ¥520,444,977.67, compared to ¥251,600,000.00 in the previous period, indicating increased leverage[85]. Inventory and Receivables - The company’s inventory shares increased by 50.53% to CNY 80,215,111.97 due to share repurchases during the reporting period[25]. - Accounts receivable increased to approximately RMB 1.03 billion from RMB 924.11 million at the end of 2018, indicating a growth in sales or credit terms[44]. - Inventory decreased to approximately RMB 264.28 million from RMB 285.44 million at the end of 2018, suggesting improved inventory management[44]. Research and Development - Research and development expenses for the current period were CNY 15,223,931.24, compared to CNY 14,174,367.04 in the previous period, indicating an increase of approximately 7.4%[64]. - The company’s research and development expenses increased to CNY 10,835,359.11 from CNY 9,032,764.91, representing a rise of 19.93%[72].